Opaleye Management Inc. Avenue Therapeutics, Inc. Transaction History

Opaleye Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.95 - $11.04 $2.9 Million - $10.9 Million	-984,692 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$9.37 - $12.06 $471,385 - $606,714	-50,308 Reduced 4.86%	984,692 $10.7 Million
Q4 2019 Feb 14, 2020	BUY	$5.26 - $9.6 $433,424 - $791,040	82,400 Added 8.65%	1,035,000 $9.94 Million
Q3 2019 Nov 14, 2019	BUY	$5.58 - $6.3 $126,108 - $142,380	22,600 Added 2.43%	952,600 $5.68 Million
Q2 2019 Aug 14, 2019	BUY	$4.33 - $6.54 $562,900 - $850,200	130,000 Added 16.25%	930,000 $5.86 Million
Q1 2019 May 15, 2019	BUY	$4.75 - $6.59 $1.44 Million - $2 Million	304,000 Added 61.29%	800,000 $3.8 Million
Q4 2018 Feb 14, 2019	BUY	$2.1 - $5.6 $1.04 Million - $2.78 Million	496,000 New	496,000 $2.68 Million

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $8.13M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.